Cargando…

Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19

Detalles Bibliográficos
Autores principales:	Vityala, Yethindra, Tagaev, Tugolbai, Mamatov, Sagynali, Aidarov, Ziiabidin, Harinath, Panchadcharam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262423/ https://www.ncbi.nlm.nih.gov/pubmed/34169913 http://dx.doi.org/10.4103/ijp.IJP_33_21

Ejemplares similares

Decreased mortality among hospitalized coronavirus disease 2019 patients who underwent anticoagulant therapy with heparin
por: Yethindra, Vityala, et al.
Publicado: (2020)

A very rare case of splenosis and acquired chronic non‐cirrhotic portal vein thrombosis with cavernous transformation
por: Kadyrova, Aliya, et al.
Publicado: (2022)

Mirror writing in a patient with frontal lobe epilepsy
por: Vityala, Yethindra, et al.
Publicado: (2021)

Use of B‐complex vitamins and olfactory training for treating COVID‐19–related anosmia
por: Vityala, Yethindra, et al.
Publicado: (2021)

A rare case of patient with neurofibromatosis type 1 in a genotype–phenotype correlation revealing a submicroscopic deletion on the long arm of chromosome 17
por: Yethindra, Vityala, et al.
Publicado: (2021)

Fine‐needle aspiration cytology‐based accurate and rapid diagnosis of breast tuberculosis mimicking an abscess
por: Vityala, Yethindra, et al.
Publicado: (2021)

A rare case of concurrent pulmonary and hepatic hydatid cysts treated by single‐stage surgical management
por: Toktogaziev, Bakyt, et al.
Publicado: (2022)

A rare case of hereditary sensory and autonomic neuropathy type II
por: Mamytova, Elmira, et al.
Publicado: (2023)

Evaluation of Cardiovascular Diseases and Diabetes Mellitus as Predisposing Factors for Mortality in Patients with Coronavirus Disease 2019: Systematic Review and Meta-Analysis
por: Yethindra, Vityala, et al.
Publicado: (2021)

CT patterns and differential criteria for acute eosinophilic pneumonia and COVID‐19 pneumonia
por: Kadyrova, Aliya, et al.
Publicado: (2021)

Severe bronchospasm following itolizumab infusion in a COVID-19 patient
por: Kumar, Neeraj, et al.
Publicado: (2022)

Adverse drug reactions of itolizumab in COVID-19 patient: A case report
por: Mohammed, Ziauddin, et al.
Publicado: (2022)

Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19
por: Kumar, Abhyuday, et al.
Publicado: (2021)

Itolizumab in Psoriasis
por: Srivastava, Ankita
Publicado: (2017)

Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab
por: Caballero, Armando, et al.
Publicado: (2020)

Plasma levels of interleukin-6 and 3-methoxy-4-hydroxyphenylglycol and treatment with milnacipran in major depression
por: Yoshimura, Reiji, et al.
Publicado: (2022)

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
por: Saavedra, Danay, et al.
Publicado: (2020)

Interleukin-6 and severity of COVID-19 patients in Hefei, China
por: Zhao, Z., et al.
Publicado: (2020)

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2017)

Increased serum interleukin-6 levels in patients with hidradenitis suppurativa
por: Xu, Haoxiang, et al.
Publicado: (2017)

Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
por: Pai, Ganesh, et al.
Publicado: (2017)

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
por: Budamakuntla, Leelavathy, et al.
Publicado: (2019)

Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2018)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Interleukin-6 level, right ventricular systolic dysfunction, and coronavirus disease 2019
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
por: Atal, Shubham, et al.
Publicado: (2020)

Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions
por: Singh, Vinay
Publicado: (2016)

Interleukin-6 and statin therapy: potential role in the management of COPD
por: Young, Robert P, et al.
Publicado: (2013)

Interleukin-6 as a potential biomarker of COVID-19 progression
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Kinetics of serum hepcidin and interleukin-6 levels following COVID-19 infection in hemodialysis patients
por: Touzot, Maxime, et al.
Publicado: (2021)

Plasma VCAM1 levels correlate with disease severity in Parkinson’s disease
por: Perner, Caroline, et al.
Publicado: (2019)

Comment on “Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis”
por: Bellan, Mattia, et al.
Publicado: (2019)

Ketamine, Interleukin-6, and Vasoplegia: Is Prevention the Best Medicine?
por: Ortoleva, Jamel P.
Publicado: (2023)

Itolizumab – a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum]
Publicado: (2015)

Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis
por: Menon, Roshni, et al.
Publicado: (2015)

Interim interleukin 6 levels correlate with progression-free survival in patients with classic Hodgkin's disease: a pilot study
por: Villanova, Pamela, et al.
Publicado: (2020)

A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis
por: Parthasaradhi, Anchala, et al.
Publicado: (2017)

Can really plasma interleukin-6 predict postoperative delirium among patients undergoing open repair surgery of acute type A aortic dissection?
por: Yang, Wen-He, et al.
Publicado: (2022)

IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia
por: Almansa, Raquel, et al.
Publicado: (2014)

IL-6 serum level and olfactory dysfunction severity in COVID-19: correspondence
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e6jslevj01cassup6a4ufve5g2